Millions of people get cataract surgery every year. Startup ForSight, backed with $125 million in fresh funding, is betting a robot can do it better than humans.
A monthly weight loss drug from Amgen helped people lose about 20% of their body weight, according to the results of a phase 2 clinical trial. If approved, the drug, called MariTide, could make Amgen the first new entrant into a market that’s been dominated by Novo Nordisk, which makes Ozempic and Wegovy, and Eli Lilly, which makes Mounjaro and Zepbound.
A dozen volunteers with severe type 1 diabetes showed clear improvements in their condition 12 months after receiving a revolutionary stem cell treatment, with all but two dropping their insulin therapy altogether. The phase 1/phase 2 clinical trial results provide hope for the 8.4 million people around the world with type 1 diabetes.
The question in this relatively new and burgeoning field is where to place your chips so you gain the best return long-term: with the top company, Intuitive Surgical, or a scrappy underdog, such as SS Innovations. There’s a good case to be made for the underdog.